aod9604 fda approved The Peptide Craze AOD 9604 in California |

Certificate fraud runs rampant throughout the research peptide supply community

Importantly, treatment did not negatively impact markers such as bone mineral density (BMD) or body weight in a manner inconsistent with healthy controls (Fawcett 2010)

The compounded market has grown significantly due to the high cost and periodic shortages of brand-name products

Research progress Support The animal experiments have achieved remarkable results: In the obese mouse model, after daily subcutaneous injection of AOD 9604 (250 g/kg) for 8 weeks, the body weight of the mice decreased by 12%, the subcutaneous fat mass decreased by 25%, and the weight of epididymal adipose tissue significantly decreased, confirming its effectiveness in fat reduction